Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 162

    1.

    Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes.

    Bar-Magen T, Sloan RD, Faltenbacher VH, Donahue DA, Kuhl BD, Oliveira M, Xu H, Wainberg MA.

    Retrovirology. 2009 Nov 11;6:103.

    PMID:
    19906306
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor.

    Goethals O, Van Ginderen M, Vos A, Cummings MD, Van Der Borght K, Van Wesenbeeck L, Feyaerts M, Verheyen A, Smits V, Van Loock M, Hertogs K, Schols D, Clayton RF.

    Antiviral Res. 2011 Aug;91(2):167-76. Epub 2011 Jun 12.

    PMID:
    21669228
    [PubMed - indexed for MEDLINE]
    3.

    Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants.

    Marinello J, Marchand C, Mott BT, Bain A, Thomas CJ, Pommier Y.

    Biochemistry. 2008 Sep 9;47(36):9345-54. Epub 2008 Aug 15.

    PMID:
    18702518
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    4.

    Characterization and structural analysis of HIV-1 integrase conservation.

    Ceccherini-Silberstein F, Malet I, D'Arrigo R, Antinori A, Marcelin AG, Perno CF.

    AIDS Rev. 2009 Jan-Mar;11(1):17-29. Review.

    PMID:
    19290031
    [PubMed - indexed for MEDLINE]
    6.

    Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes.

    Maïga AI, Malet I, Soulie C, Derache A, Koita V, Amellal B, Tchertanov L, Delelis O, Morand-Joubert L, Mouscadet JF, Murphy R, Cissé M, Katlama C, Calvez V, Marcelin AG.

    Antivir Ther. 2009;14(1):123-9.

    PMID:
    19320246
    [PubMed - indexed for MEDLINE]
    7.

    Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor.

    Bar-Magen T, Sloan RD, Donahue DA, Kuhl BD, Zabeida A, Xu H, Oliveira M, Hazuda DJ, Wainberg MA.

    J Virol. 2010 Sep;84(18):9210-6. Epub 2010 Jul 7.

    PMID:
    20610719
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    8.

    Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors.

    Serrao E, Odde S, Ramkumar K, Neamati N.

    Retrovirology. 2009 Mar 5;6:25. Review. Erratum in: Retrovirology. 2009;6:33.

    PMID:
    19265512
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    9.

    HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays.

    Bar-Magen T, Donahue DA, McDonough EI, Kuhl BD, Faltenbacher VH, Xu H, Michaud V, Sloan RD, Wainberg MA.

    AIDS. 2010 Sep 10;24(14):2171-9.

    PMID:
    20647908
    [PubMed - indexed for MEDLINE]
    10.

    Lack of primary mutations associated with integrase inhibitors among HIV-1 subtypes B, C, and F circulating in Brazil.

    Passaes CB, Guimarães ML, Fernandez SL, Lorete Rdos S, Teixeira SL, Fernandez JC, Morgado MG.

    J Acquir Immune Defic Syndr. 2009 May 1;51(1):7-12.

    PMID:
    19262402
    [PubMed - indexed for MEDLINE]
    11.

    Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.

    Ceccherini-Silberstein F, Van Baelen K, Armenia D, Trignetti M, Rondelez E, Fabeni L, Scopelliti F, Pollicita M, Van Wesenbeeck L, Van Eygen V, Dori L, Sarmati L, Aquaro S, Palamara G, Andreoni M, Stuyver LJ, Perno CF.

    Antimicrob Agents Chemother. 2010 Sep;54(9):3938-48. Epub 2010 May 17.

    PMID:
    20479206
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    12.

    Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy.

    Buzón MJ, Marfil S, Puertas MC, Garcia E, Clotet B, Ruiz L, Blanco J, Martinez-Picado J, Cabrera C.

    Antivir Ther. 2008;13(7):881-93.

    PMID:
    19043922
    [PubMed - indexed for MEDLINE]
    13.

    HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.

    Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Bénard A, Campa P, Chêne G, Brun-Vézinet F, Descamps D; French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2).

    J Antimicrob Chemother. 2008 Nov;62(5):914-20. Epub 2008 Aug 20.

    PMID:
    18718922
    [PubMed - indexed for MEDLINE]
    Free Article
    14.

    Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates.

    Van Wesenbeeck L, Rondelez E, Feyaerts M, Verheyen A, Van der Borght K, Smits V, Cleybergh C, De Wolf H, Van Baelen K, Stuyver LJ.

    Antimicrob Agents Chemother. 2011 Jan;55(1):321-5. Epub 2010 Oct 18.

    PMID:
    20956600
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    15.

    HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase.

    Espeseth AS, Felock P, Wolfe A, Witmer M, Grobler J, Anthony N, Egbertson M, Melamed JY, Young S, Hamill T, Cole JL, Hazuda DJ.

    Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11244-9.

    PMID:
    11016953
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    16.

    Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.

    Malet I, Delelis O, Valantin MA, Montes B, Soulie C, Wirden M, Tchertanov L, Peytavin G, Reynes J, Mouscadet JF, Katlama C, Calvez V, Marcelin AG.

    Antimicrob Agents Chemother. 2008 Apr;52(4):1351-8. Epub 2008 Jan 28.

    PMID:
    18227187
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    17.

    Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy.

    McColl DJ, Chen X.

    Antiviral Res. 2010 Jan;85(1):101-18. Epub 2009 Nov 17. Review.

    PMID:
    19925830
    [PubMed - indexed for MEDLINE]
    18.

    Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143.

    Métifiot M, Vandegraaff N, Maddali K, Naumova A, Zhang X, Rhodes D, Marchand C, Pommier Y.

    AIDS. 2011 Jun 1;25(9):1175-8.

    PMID:
    21505303
    [PubMed - indexed for MEDLINE]
    19.

    HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.

    da Silva D, Van Wesenbeeck L, Breilh D, Reigadas S, Anies G, Van Baelen K, Morlat P, Neau D, Dupon M, Wittkop L, Fleury H, Masquelier B.

    J Antimicrob Chemother. 2010 Jun;65(6):1262-9. Epub 2010 Apr 12.

    PMID:
    20388636
    [PubMed - indexed for MEDLINE]
    Free Article
    20.

    Induced-fit docking approach provides insight into the binding mode and mechanism of action of HIV-1 integrase inhibitors.

    Barreca ML, Iraci N, De Luca L, Chimirri A.

    ChemMedChem. 2009 Sep;4(9):1446-56.

    PMID:
    19544345
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk